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Dendritic cell (DC) activation is essential for the
induction of immune defense against pathogens,
yet needs to be tightly controlled to avoid chronic
inflammation and exaggerated immune responses.
Here, we identify a mechanism of immune homeo-
stasis by which adaptive immunity, once triggered,
tempers DC activation and prevents overreac-
tive immune responses. T cells, once activated, pro-
duced Protein S (Pros1) that signaled through TAM
receptor tyrosine kinases in DCs to limit the magni-
tude of DC activation. Genetic ablation of Pros1 in
mouse T cells led to increased expression of cos-
timulatory molecules and cytokines in DCs and
enhanced immune responses to T cell-dependent
antigens, as well as increased colitis. Additionally,
PROS1 was expressed in activated human T cells,
and its ability to regulate DC activation was con-
served. Our results identify a heretofore unrecog-
nized, homeostatic negative feedback mechanism
at the interface of adaptive and innate immunity
that maintains the physiological magnitude of the
immune response.
INTRODUCTION
The innate immune response functions as both the first line
of defense against pathogens and also as the initiating
trigger for adaptive immunity (Iwasaki and Medzhitov, 2010;
Janeway, 1989; Medzhitov et al., 1997). Activation of dendritic
cells (DCs), the professional antigen-presenting cells, drives
T cell activation. These essential functions notwithstanding,160 Immunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc.the magnitude of DC activation must be precisely controlled.
Unrestrained DC responses can lead to pathological
conditions characterized by overreactive immune responses,
such as allergy, autoimmunity, and chronic inflammatory
diseases (Coombes and Powrie, 2008; Lambrecht and
Hammad, 2010). A priori, the induction of T cell activation must
be coupled to a homeostatic negative feedback mechanism
that limits the function of DCs. Such a mechanism
would still allow T cell activation and initiation of adaptive
immunity by DCs, yet enable T cells, once activated, to signal
back to DCs and restrain further stimulation of the immune
response.
Receptor tyrosine kinases (RTKs) of the TAM family, Axl and
Mertk, are pleiotropic negative regulators of Toll-like receptor
(TLR) and cytokine receptor signaling in DCs (Rothlin et al.,
2007). Two ligands for the TAM receptors, Protein S (Pros1)
and Gas6, have been identified by in vitro approaches (Stitt
et al., 1995). Although the source of the ligands that activate
TAM receptors in DCs in vivo is unknown, T cell-dependent
activation of TAM receptors would allow for an inflammatory
response in DCs upon initial pathogen encounter, followed by
downregulation of this response once antigen presentation
and T cell activation have occurred. Therefore, we considered
the possibility that T cells might be an important source of
TAM ligands. Here, we show that Pros1 was expressed by
mouse and human activated T cells and inhibited DC func-
tion. Although Pros1 is well known to function as an essential
anticoagulant where its action is TAM-independent (Burstyn-
Cohen et al., 2009; Dahlba¨ck, 2007), we reveal an anti-
inflammatory function of T cell-derived Pros1 as the in vivo
TAM ligand. Our results also reveal that this T cell-derived
Pros1-DC TAM signaling axis is an indispensable, evolutionarily
conserved, homeostatic feedback mechanism by which adap-
tive immunity controls the magnitude of the innate immune
response.
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Figure 1. Activated T Cells Express Pros1
(A) Splenic CD4+ T cells from OT-II mice were cocultured with BM-DC alone or in the presence of 200 mg/mL OVA for 24 hr. Pros1 induction was analyzed after
antigen-specific activation of CD4+ T cell (CD4+CD69+). Representative FACS plots (left) and MFI for Pros1 expression on CD4+ T cells (right) are shown.
(B) CD45.2 T cells from indicated genotypes were transferred into CD45.1 recipients and 1 day after transfer recipient micewere injected into the rear footpadwith
50 mg of OVA/IFA/LPS. Popliteal and inguinal LNs were collected 48 hr after immunization. Representative plots show CD45.2 transferred T cells and Pros1
expression in Ctrl OT-II T cells compared with Pros1/ OT-II T cells.
(C) Splenic CD4+ cells were isolated and activated in vitro with anti-CD3 and anti-CD28. Pros1 mRNA expression was determined by qPCR and normalized to
unstimulated cells.
(D) Representative FACS histograms of Pros1 expression on resting and activated CD4+ T cells with anti-CD3 and anti-CD28 for 15 hr. Gray histogram represents
activated CD4+ cells from Pros1flox/flox Cd4-Cre+ (Pros1/) mice. Data are presented as representative individual samples or as mean ± SEM of at least 4 to 6
independent samples per group. *p < 0.05, ***p < 0.001. See also Figure S1.
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Activated T Cells Express Pros1
To test the hypothesis that activated T cells constitute a relevant
immunological source of Pros1, we first measured Pros1 expres-
sion upon antigen presentation in vitro. Activation of OT-II trans-
genic CD4+ T cells upon incubation with bone marrow (BM)-DCs
in the presence of ovalbumin (OVA) in vitro led to the detection of
Pros1 on activated T cells (Figure 1A). Next, we generated a
mouse where Pros1 expression was genetically ablated specif-ically in T cells. Mice homozygous for ‘‘floxed’’ Pros1 alleles
(Burstyn-Cohen et al., 2009) were crossed with mice expressing
CRE recombinase under the control of the Cd4 promoter.
Although completePros1-deficientmice die in utero due to fulmi-
nant coagulopathy (Burstyn-Cohen et al., 2009; Saller et al.,
2009),Pros1flox/floxCd4-Cre+micewere viable. T cells do not sub-
stantially contribute to the physiological amounts of Pros1 in
plasma because the amounts of Pros1 in the plasma of control
and Pros1flox/floxCd4-Cre+mice were comparable (see Figure S1
available online). Furthermore, no overt defects in thymicImmunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc. 161
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T Cell-Derived Protein S Regulates DC Activationdevelopment or on activation of splenic T cells were detected in
Pros1flox/floxCd4-Cre+ mice at 2–4 months of age (Figure S1). To
directly test whether activated, antigen-specific T cells express
Pros1 in vivo, we crossed Pros1flox/floxCd4-Cre+ to OT-II trans-
genic mice. Next, we transferred control and Pros1/ OT-II
CD45.2+ CD4+ T cells into CD45.1+ recipient mice and immu-
nized them with OVA-LPS-IFA in their footpads (Figure 1B).
Pros1 expression was detected in activated antigen-specific
T cells in vivo (Figure 1B). Finally, direct activation of isolated
murine splenic CD4+ T cells via anti-CD3 and anti-CD28 stimula-
tion led to the upregulation of Pros1 messenger RNA (mRNA)
(Figure 1C) and protein (Figure 1D). Consistent with the genetic
ablation of Pros1 in T cells, this upregulation was undetectable
in in vitro activated T cells from Pros1flox/floxCd4-Cre+ mice (Fig-
ure S1). Resting CD4+ T cells did not express Pros1 (Figure 1D).
Similar results were obtained by using T cells from Pros1flox/flox
Lck-Cre+ mice. Neither resting nor activated T cells expressed
Gas6 (data not shown). Taken together, these results indicate
that T cells, activated in an antigen-specific manner, express
Pros1.
Deficiency of Pros1 in T Cells Leads to Accelerated
Disease Onset in a Model of Induced Colitis
The transfer of CD4+CD25CD45RBhi cells into Rag1/ mice
results in the induction of colitis, a disease dependent on mi-
crobiota and triggered by antigen-specific DCs (Coombes
and Powrie, 2008; Feng et al., 2010). We hypothesized that
whether T cell-derived Pros1 limits DC activation in vivo, trans-
fer of Pros1/CD4+CD25CD45RBhi cells into Rag1/ mice
would result in exacerbated colitis. Indeed, transfer of Pros1/
naive T cells led to a substantial acceleration of disease onset,
as indicated by higher colonoscopy scores (Figure 2A; Fig-
ure S2). Increased numbers of interferon-g (IFN-g) and inter-
leukin-17A (IL-17A) expressing T cells were detected in the
mesenteric lymph nodes of Pros1/CD4+CD25CD45RBhi re-
cipients, relative to the control CD4+CD25CD45RBhi recipi-
ents (Figure 2B–2D). Similarly, higher numbers of IL-17A
expressing T cells were detected in the lamina propria of
mice receiving Pros1/ naive T cells (Figure 2E). These results
indicate that Pros1 expression in T cells limits pathological
inflammation.
T Cell-Derived Pros1 Limits DC Activation
Next, we directly tested whether T cell-derived Pros1 regulates
DC activation in vivo. Control and Pros1-deficient OT-II
CD45.2+CD4+ T cells were transferred into CD45.1+ recipient
mice, which were subsequently immunized with OVA-LPS-IFA
in their footpads. Remarkably, the loss of Pros1 in antigen-spe-
cific T cells resulted in a significant increase in the population of
activated DCs, as detected by the expression of the costimula-
tory molecules CD86 and CD40, in the draining lymph node
(Figure 3A). Similarly, we detected an enhancement in the activa-
tion of DCs when Pros1flox/floxCd4-Cre+ mice were directly
immunized with OVA-LPS-IFA (Figure S2). Given these findings,
we tested the ability of T cell-derived Pros1 to directly regulate
the magnitude of DC activation upon antigen presentation
in vitro. We cocultured CD4+CD25 cells obtained from either
Pros1flox/floxCd4-Cre+ OT-II or Pros1flox/floxCd4-Cre OT-II
mice with BM-DCs in the presence of OVA. In agreement162 Immunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc.with an immunomodulatory function of T cell-derived Pros1,
we detected a significant increase in the percentage of CD86+
and CD40+ BM-DCs when cultured with Pros1-deficient as
opposed to Pros1-expressing OT-II T cells (Figure 3B). Further-
more, tumor necrosis factor-a (TNF-a) and IL-6 production
were also increased in the absence of T cell-derived Pros1
(Figures 3C and 3D). Importantly, Pros1 produced by acti-
vated T cells did not exert an autocrine effect: There were no
significant differences in the expression of activation markers,
production of cytokines, and proliferation between control
(Pros1flox/floxCd4-Cre or Pros1wt/wtCd4-Cre+) and Pros1-defi-
cient T cells when they were activated in vitro with anti-CD3
and anti-CD28 (Figure S3). In agreement with the increased
activation of DCs in the absence of T cell-derived Pros1,
Pros1flox/floxCd4-Cre+mice immunizedwith OVA-LPS-IFA devel-
oped larger lymph nodes in comparison to control mice, primar-
ily due to an expansion of T cells (Figure S2). Furthermore, we
detected an increase in the proliferation of Pros1/ CD4+
T cells isolated 10 d.p.i. when they were restimulated with OVA
in vitro, as well as higher amounts of IL-2 in the culture superna-
tant (Figure S2). Similarly, when control or Pros1/ OT-II T cells
were transferred into mice that were subsequently immunized
with OVA-LPS-IFA, we detected significantly higher numbers
of transferred OT-II T cells and increased cellularity of the drain-
ing lymph nodes in those mice that received Pros1 deficient
antigen-specific T cells (Figure S2). These findings are consistent
with an increase in the number of antigen-specific T cells gener-
ated in the absence of T cell-derived Pros1.
To further confirm whether T cells are a relevant source of
Pros1 for immunomodulation, we compared the immune
response of control and Pros1flox/floxCd4-Cre+ mice to T-depen-
dent and T-independent antigens. Pros1flox/floxCd4-Cre+ mice
developed significantly higher titers of antitrinitrophenyl (TNP)
immunoglobulin G1 (IgG1) in comparison to control mice upon
immunization with the hapten TNP linked to keyhole limpet hae-
mocyanin (KLH), a T-dependent antigen (Figure 4A). Conversely,
no differences between Pros1flox/floxCd4-Cre+ and control mice
were detected upon immunization with the T-independent anti-
gen TNP-Ficoll (Figure 4B). Interestingly, by 9 months of age,
Pros1flox/floxCd4-Cre+ mice showed a spontaneous expansion
of CD4+CD44hiCD62L cells (Figure S4). However, autoanti-
bodies, such as anti-DNA antibodies, were not detectable in 6-
to 9-month-old mice (Figure S4). Taken together, the above
results indicate that Pros1 expression in activated antigen-spe-
cific T cells is required for the homeostatic regulation of the
magnitude of DC activation, thus ensuring a physiological
immune response.
T Cell-Derived Pros1 Acts Locally to Inhibit DC
Activation through TAM Signaling
Pros1 carries an N-terminal g-carboxyglutamic acid (GLA)-rich
domain that allows it to bind to cell membranes containing the
negatively charged phospholipid, phosphatidylserine (PtdSer).
Binding of Pros1 to PtdSer is an essential feature of its biolog-
ical activity (Nyberg et al., 1997). Interestingly, PtdSer is tran-
siently exposed on the outer leaflet of the plasma membrane
of activated T cells (Figure S5; Fischer et al., 2006). This
feature prompted us to test whether T cell-derived Pros1 func-
tioned locally, at the interface of DC-T cell interaction, by
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Figure 2. Deficiency of Pros1 in Transferred T Cells Leads to Accelerated Colitis in Rag1–/– Recipient Mice
Sorted CD4+CD25CD45RBhi T cells from Pros1flox/flox Cd4-Cre (Ctrl) or Cre+ (Pros1/) were transferred i.p. into Rag1/ mice and colitis development was
monitored.
(A) Colonoscopy score of disease severity.
(B) Representative intracellular FACS staining for IFN-g and (C) IL-17A production on CD4+ cells from mesenteric LN.
(D) Percentage of IFN-g+ and IL-17A+ CD4+ cells in the mesenteric LN.
(E) Representative intracellular FACS staining for IL-17A (left) and percentage of IL-17A+CD4+ cells (right) in lamina propria leukocytes of large intestine. Data are
presented as individual samples or as mean ± SEM and are representative of two independent experiments with at least five samples per group. *p < 0.05, **p <
0.01. See also Figure S2.
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T Cell-Derived Protein S Regulates DC Activationphysically separating DC and T cells with a transwell system.
To this end, we utilized T cells that had been prestimulated
in vitro with anti-CD3 and anti-CD28 to bypass the need for
DC-T cell contact to induce Pros1 expression in the T cells.
Splenic CD4+CD25 T cells were activated in vitro and were
then cocultured with BM-DCs in the presence of several
different agonists of pattern recognition receptors. BM-DCs
expressed higher amounts of CD86 and CD40 in response to
poly I:C when cocultured with Pros1-deficient versus control
T cells (Figure S5). Furthermore, the production of many
different cytokines (TNF-a, IL-6, IFN-b) was significantly higher
when BM-DCs were activated in the presence of Pros1/T cells than control T cells (Figure S5). Similarly, the activation
of BM-DCs with CpG-A was also higher when DCs were cocul-
tured with Pros1-deficient T cells than with control T cells (Fig-
ure S5). Addition of recombinant Pros1 to the cocultures
rescued the ability of activated Pros1/ T cells to regulate
DC function (Figure S6). Next, we utilized the transwell system
to physically separate in vitro activated T cells from BM-DCs.
Interestingly, no differences in the expression of activation
markers (e.g., costimulatory molecules) were detected when
BM-DCs were cultured across the transwell with either control
or Pros1/ T cells (Figure 5A). These results suggest that
Pros1-TAM signaling is not engaged in the presence of aImmunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc. 163
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Figure 4. Deletion of Pros1 in T Cell Results in Increased Immune Responses upon Immunization with T-Dependent Antigens
(A) Serum TNP-specific IgG1 in TNP-KLH-immunized Pros1flox/flox Cd4-Cre or Pros1flox/flox Cd4-Cre+ mice.
(B) TNP-specific IgG3 in TNP-Ficoll-immunized mice. Data are presented as mean ± SEM and are representative of two independent experiments with at least
four samples per group. **p < 0.01, ***p < 0.01. See also Figure S4.
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T Cell-Derived Protein S Regulates DC Activationpermeable but physical barrier. Binding to exposed PtdSer on
activated T cells might restrict Pros1 to the T cell surface, ac-
counting for this localized function. Because Annexin V has
been shown to efficiently compete with Pros1 for PtdSer bind-
ing (Anderson et al., 2003; Webb et al., 2002), we compared
the activation of BM-DCs cocultured with activated T cells in
the absence or presence of Annexin V. Addition of Annexin V
to the coculture led to a significant enhancement of the
expression of CD86 and CD40 by BM-DCs upon poly I:C stim-
ulation in wild-type (WT) but not Pros1-deficient T cells (Fig-
ure 5B; Figure S6). These results indicate that Pros1 binding
to PtdSer is necessary for its immunomodulatory effect.
We also tested whether the loss of Axl and Mertk signaling in
DCs phenocopied the loss of Pros1 in T cells by using the
in vitro antigen-presentation assay. When cocultured with
Pros1-expressing OT-II T cells, BM-DCs lacking both Axl and
Mertk (Axl/Mertk/) expressed substantially higher amounts
of costimulatory molecules, relative to WT BM-DCs (Figure 5C).
These results indicate that the loss of Axl andMertk renders DCs
refractory to T cell-derived Pros1-mediated regulation. TAM
signaling regulates the degree of DC activation through the
induction of Socs, which in turn leads to reduction of NF-kB
activity (Rothlin et al., 2007). The use of Pros1-deficient T cells
in the T cell:DC coculture system led to the reduced induction
of Socs3, increased IkBa degradation, and increased p65
NF-kB phosphorylation in BM-DCs in comparison to control
T cells (Figures 5D–5F). Together, all of these data demonstrate
that T cell-derived Pros1 functions locally at the DC-T cell
interface and engages TAM signaling within DCs to limit their
activation.Figure 3. T Cell-Derived Pros1 Limits DC Activation
(A) CD45.2 T cells from indicated genotypes were transferred into CD45.1 recipie
LPS into the rear footpad. Popliteal and inguinal LNs were collected after 72 hr an
histograms for nonimmunized and OVA immunized mice and independent data a
(B) Splenic CD4+CD25 T cells were isolated from Pros1flox/flox Cd4-Cre OT-II
cocultured with BM-DCs in the presence of the indicated concentrations of OVA. R
CD11c+ cells are shown.
(C) TNF-a and IL-6 production in the coculture supernatants after 72 hr, as meas
(D) Representative plots showing intracellular staining for TNF-a and IL-6 in C
representative individual samples or as mean ± SEM of 3–5 independent samplePROS1 Expression and Function Are Conserved
in Humans
To test whether human T cells express PROS1, human naive
CD4+ T cells were isolated by negative selection from human
peripheral blood mononuclear cells (PBMCs) and stimulated
with anti-CD3 plus anti-CD28. In vitro activation of human
CD4+ T cells led to a significant induction of PROS1 mRNA as
well as PROS1 expression on the cell surface (Figures 6A and
6B). We also compared PROS1 expression in the interfollicular
T cell area of reactive versus nonreactive human lymph nodes.
Sections from nonmalignant human lymph nodes classified by
histopathological analyses as nonreactive (n = 6) or reactive
(n = 6) were stained with anti-CD3 and anti-PROS1 antibodies
and counterstained with hematoxylin. PROS1 staining was pos-
itive in the CD3+ T cell area of reactive lymph nodes with no
expression detectable in nonreactive lymph nodes (Figure 6C).
To explore whether human T cell-derived PROS1 indeed func-
tions in regulating the degree of DC activation, we performed
mixed lymphocyte reactions (MLRs). Monocyte-derived DCs
and naive T cells were isolated from different donors and cocul-
tured for 5 days. Monocyte-derived DCs express both AXL and
MERTK, whereas activated T cells express PROS1 in the MLR
(data not shown). In agreement with a regulatory role for
PROS1, the neutralization of PROS1 with an anti-PROS1 anti-
body led to a significant increase in CD86 and CD40 expression
in human monocyte-derived DCs (Figures 6D and 6E).
To test whether the loss of function of PROS1 is associated
with pathological inflammation in humans, we extended our
studies to patients with Inflammatory Bowel Disease (IBD),
including Ulcerative Colitis and Crohn’s Disease. PROS1nts and 1 day after transfer recipient mice were injected with 50 mg of OVA/IFA/
d CD86 and CD40 expression were measured on CD11c+ cells. Representative
re shown.
(Ctrl OT-II Tc) and Pros1flox/flox Cd4-Cre+ OT-II (Pros1/OT-II Tc) mice and
epresentative FACS histograms and percentage of CD86+ CD11c+ and CD40+
ured by ELISA.
D11c+ (left) and individual samples (right) are shown. Data are presented as
s per group. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S2 and S3.
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Figure 5. Negative Feedback of T Cell-Derived Pros1 Depends of Cell Proximity and Axl and Mertk Signaling on DCs
(A) Splenic CD4+ CD25 T cells from Pros1flox/flox Cd4-Cre (Ctrl Tc) or Pros1flox/flox Cd4-Cre+ (Pros1/) mice were activated in vitro with anti-CD3 and anti-CD28
for 4 hr. Activated T cells were then cocultured with BM-DCs in presence of 30 mg/mL of poly I:C for 15 hr. To prevent close contact between activated CD4+
T cells and BM-DCs, we cultured BM-DCs on the upper chamber of a transwell system, whereas we cultivated activated T cells on the lower chamber. MFI of
CD86 and CD40 expression on CD11c+ cells in the indicated conditions are shown.
(B) Where indicated, 10 mg/mL of Annexin V (AnxV) was added to the T cell culture 1 hr prior to coculture with BM-DCs. Representative FACS histograms of CD86
and CD40 expression on CD11c+ cells are shown.
(C) CD4+CD25OT-II Ctrl T cells were coculturedwithWT orAxl/Mertk/BM-DC in the presence of 200 mg/mL of OVA for 48 hr. Representative histograms for
CD86 and CD40 expression on CD11c+ cells are shown.
(D) Percentage of CD11c+SOCS3+ in activated BM-DCs upon coculture with Ctrl or Pros1/ T cells.
(E) IkBa (top) and Tubulin (bottom) in the coculture were analyzed by immunoblot at the indicated time points.
(F) Phospho-NF-kB p65 (Ser536) subunit was measured on activated CD11c+ cell cocultured with Ctrl or Pros1/ T cells by FACS. Data are presented as
percentage of phospho-NF-kBp65 onCD11c+ cells, by histograms. Data are presented as individual samples or asmean ± SEMand are representative of at least
two independent experiments with three to four independent samples per group. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S5 and S6.
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T Cell-Derived Protein S Regulates DC Activationamounts are measured routinely from patient plasma for the
diagnosis of PROS1 deficiencies. Interestingly, patients with
active IBD frequently showed lower amounts of plasma PROS1
relative to healthy controls (Figure 6F). More than 200 germline
mutations in the PROS1 gene have been described. Type I defi-
ciencies, characterized by reduced PROS1 amounts, are associ-
ated with mutations within the coding region (Gandrille et al.,
2000; Garcı´a de Frutos et al., 2007). Therefore, for Type I
deficiencies, the plasma concentration of PROS1 (produced
by hepatocytes and endothelial cells) is likely to function as a
surrogate for the amount of PROS1 produced by other cellular
sources, including T cells. Future studies directly measuring
T cell-derived PROS1 will further validate this hypothesis.
Collectively, these results indicate that this anti-inflammatory166 Immunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc.pathway is present in humans and functions in maintaining
immune homeostasis.
DISCUSSION
Our results reveal a hitherto unknown indispensable, negative
feedbackmechanism bywhich activated T cells restrain DC acti-
vation and, thereby, regulate the overall magnitude of the
immune response. Following initial DC activation and antigen
presentation, T cells are activated, leading to the induction of
Pros1. Pros1 engages the anti-inflammatory TAM receptor tyro-
sine kinase signaling pathway in DCs. This enables activated
T cells to report back to DCs and restrain further stimulation of
the overall immune response. This feedback mechanism is
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Figure 6. PROS1 Is Expressed in Activated Human CD4 T Cells and PROS1 Blockade Leads to Enhanced Activation of DCs in MLR
Human naive CD4 T cells were isolated from PBMCs by negative selection and stimulated with anti-CD3 and anti-CD28 for 6 days.
(A) Expression of PROS1 mRNA, normalized to unstimulated naive CD4+ T cells. Data are presented as mean ± SEM of at least five samples per condition.
(B) Surface PROS1 expression on CD4+CD69+ cells after 6 days of stimulation with anti-CD3 and anti-CD28. Representative histogram from at least five
independent donors is shown.
(C) Sections from nonreactive and reactive human lymph nodes (LNs) were stained with anti-CD3 and anti-PROS1. Representative PROS1 staining in the
interfollicular CD3+ T cell areas on nonreactive (n = 6) and reactive (n = 6) LNs are shown.
(D and E) CD86 and CD40 expression were measured on CD11c+ cells at day 5. Representative histograms (left) and independent data with at least three
independent samples per group (right) are shown. Each experiment was repeated at least twice employing three to five different donors.
(F) Percentage of total PROS1 in healthy controls (n = 9) and IBD patients (n = 11). Horizontal lines indicate the mean in each group. Total PROS1 was determined
using automated latex immunoassay methodology and normalized to an average value of PROS1 from a pool of healthy donors. *p < 0.05, **p < 0.01, ***p < 0.01.
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T Cell-Derived Protein S Regulates DC Activationessential for maintaining the physiological balance of immune
activation capable of host defense yet avoiding exacerbated
inflammation. The absence of this ‘‘immunological brake’’ leads
to pathological inflammation and chronic inflammatory diseases,
such as colitis. Importantly, Pros1-TAM signaling is not redun-
dant with respect to other negative regulators. Although Pros1
is a secreted protein, its immunoregulatory function is depen-
dent on its binding to the T cell-surface associated PtdSer,
thereby restricting Pros1 function to DC-T cell interface.
Because cognate DC-T cell interactions are antigen-specific,
this property of Pros1 presumably results in an antigen-specific
negative regulatory function. Whether this feature makes Pros1
distinct from other known negative regulators of DC activation,
such as IL-10 (Banchereau et al., 2012), and prevents compen-sation remains unknown. Future studies focused on Pros1 func-
tion in a variety of immunological settings and its integration with
known regulatory pathways will provide a more comprehensive
understanding of mechanisms through which the adaptive
immune system, once engaged, regulates the magnitude of
the innate immune response and how overall immune homeo-
stasis is maintained.
Pros1, produced by hepatocytes and endothelial cells, is
found in large amounts in the blood (Burstyn-Cohen et al.,
2009). T cells do not substantially contribute to the physiological
amounts of Pros1 in plasma because the concentrations of
Pros1 in the plasma of control and Pros1flox/floxCd4-Cre+mice
were comparable. Conversely, our findings unambiguously
demonstrate that Pros1 in the blood is unable to compensateImmunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc. 167
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T Cell-Derived Protein S Regulates DC Activationfor the loss of Pros1 expression by activated T cells. The fact that
T cell-derived Pros1 is necessary to control DC responses,
despite a substantial amount of Pros1 being present in the circu-
lation, is intriguing. Our results demonstrate that Pros1 acts
locally as an immunomodulatory signal at the physical T cell-
DC interface. The simultaneous production of Pros1 and the
exposure of PtdSer on activated T cells allows for the localization
and the bioactivity of Pros1 at the T cell membrane surface,
engaging TAM signaling in DCs following T cell priming in
lymphoid organs. Additionally, Pros1 in the plasma, an approxi-
mately 72 kDa molecule in its monomeric form, is likely to be
excluded from the extravascular sites where DC-T cell inter-
action occurs. A local, circulation-independent production of
Pros1 has also recently been observed for retinal pigment
epithelial cells of the eye (Burstyn-Cohen et al., 2012).
There are two known ligands for the TAM receptors—Gas6
and Pros1. These ligands often function redundantly. For
example, Gas6/ mice do not recapitulate the phagocytosis
defects in the retinal pigmental epithelial cells observed in
Mertk/ mice (Prasad et al., 2006). The combinatorial deletion
of Gas6 and Pros1 in the retina is required to phenocopy the
loss of Mertk (Burstyn-Cohen et al., 2012). Interestingly, neither
resting nor activated T cells express Gas6. Consistent with this
expression pattern, the loss of Pros1 alone in T cells is sufficient
to account for the enhancedmagnitude of the immune response.
Albeit fundamental and nonredundant for controlling the magni-
tude of the immune response and preventing pathological
inflammatory responses, loss of T cell-derived Pros1, by itself,
is not enough to spontaneously break tolerance. TAM receptors
have two major biological functions—the removal of apoptotic
cells and the negative regulation of innate immune responses.
The loss of these distinct functions likely accounts for the auto-
immunity in TAM triple-deficient mice. Thus, the combinatorial
deletion of the two ligands might be required to recapitulate
the spontaneous autoimmunity characteristic of TAM triple-
deficient mice.
Our results reveal the hitherto unknown function of Pros1 as an
endogenous anti-inflammatory protein and a key regulator of im-
mune homeostasis. The most well-established activity of Pros1
to date is TAM-independent, in which it functions as an anticoag-
ulant (Gandrille et al., 2000). In fact, Smiley et al. reported the
expression of Pros1 in activated T cells yet ascribed this to an
anticoagulant role of T cells (Smiley et al., 1997). Is the duality
of Pros1 function relevant in physiological or pathological set-
tings? Chronic inflammatory and autoimmune diseases have
been described anecdotally, yet repeatedly, in patients with
low circulating amounts of PROS1 (Aadland et al., 1992;
Koutroubakis et al., 2000; Suh et al., 2010; Zezos et al., 2007).
Additionally, diseases, such as IBD, are often concurrent with
thrombotic events (Grainge et al., 2010). The discovery of the
novel immunomodulatory function of Pros1 might provide a uni-
fyingmolecular explanation for these two clinical features of IBD.
The association of reduced PROS1 with IBD supports the notion
that there might be a causal link. However, thrombotic events
can directly lead to inflammation, and our present results do
not rule out an association between IBD and a subset of patients
with PROS1 loss limited to the plasma. On the other hand, we are
also likely to miss patients with T cell-specific loss of PROS1
because T cells do not contribute to the plasma concentration168 Immunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc.of PROS1. Nevertheless, the association is intriguing, and dedi-
cated efforts focused on measuring T cell-derived PROS1 might
causally link PROS1 deficiencies with the development and
progression of autoimmune or chronic inflammatory diseases,
as well as reveal PROS1 as a useful biomarker for minimally inva-
sive diagnosis and prognosis of IBD in the future.
EXPERIMENTAL PROCEDURES
Mice
Pros1flox/flox, Axl/Mertk/ mice have been described previously (Burstyn-
Cohen et al., 2009; Lu et al., 1999). Cd4-Cre, Lck-Cre, B6.Cg-Tg (TcraTcrb)
(OT-II) transgenic mice, Rag1/, and B6.SJL-PtprcaPepcb/BoyJ (CD45.1)
were obtained from Jackson Laboratory. All mice were bred at Yale University
animal facility. All mice were specific-pathogen free, maintained under a strict
12 hr light cycle (lights on at 7:00 a.m. and off at 7:00 p.m.), and given a regular
chow diet. All experimental procedures were approved by Yale IACUC.
Antibodies
The following anti-mouse antibodies were purchased from BD-Biosciences,
eBioscience, Santa Cruz or BioLegend (USA), as conjugated to FITC, PE,
PE-Cy5, PerCP-Cy5.5, APC-Cy7, Alexa Fluor 700, PE-Cy7, Pacific Blue, or
APC: CD3 (145-2C11), CD4 (GK1.5, L3T4, RM4-5), CD8 (53-6.7), CD11b
(MI/70), CD11c (N418, HL3), CD25 (PC61), CD40 (HM40), CD44 (IM7), CD45
(30-F11), CD45R (RA3-6B2), CD62L (MEL-14), CD69 (H1.2F3), CD86 (GL1),
F4/80 (BM8), I-A/I-E (M5/114.15.2), IL-6 (MP5-20F3), IL-12p40 (C17.8),
TNF-a (MP6-XT22), IFN-g (XMG1.2), IL-17A (17B7). Unconjugated antibodies
employed were CD3 (145-2C11), CD28 (37.51), IL-4 (11B11), IFN (XMG1.2),
Protein S (H90): sc 25836, CD16/32 (2.4G2).
As a secondary antibody, DyLight 649 donkey anti-rabbit IgG (Poly4064)
was used. Monoclonal antibody against human GLA residues (American Diag-
nostica) was used to immunoprecipitate GLA containing proteins from serum.
The following anti-human antibodies were purchased from BD-Biosciences
or BioLegend (USA), conjugated to Alexa Fluor 488, FITC, APC-Cy7, APC, PE,
Pacific Blue: CD2 (TS1/8), CD69 (FN50), CD3 (UCHT1), CD4 (RPA-T4), CD11c
(3.9), CD11b (MI/70), CD40 (5C3), CD86 (IT2.2), and PROS1 (PS7).
Flow Cytometry Analysis
For standard stainings, cells were harvested and washed once with PBS and
then blocked with Fc-block (BD- Bioscience) for at least 10 min in PBS-2%
FBS. Cells were washed again and incubated with the respective cocktail of
antibodies for 30 min on ice. Antibody cocktails were prepared in PBS-2%
FBS. 7ADD was also included to gate on live cells. After the last wash, cells
were acquired on a FACSCalibur, LSR-II (BD) or Stratedigm S1000EX
(Stratedigm).
For Pros1 staining, after cells were collected and washed, they were fixed
with cold acetone (20C) for 5 min and washed three times with PBS to
discard all remaining acetone. After washing, cells were blocked with
PBS-3% BSA for 30 min on ice. They were washed again and anti-Pros1
(H90) (Santa Cruz Biotechnology, USA) was added at 1 mg per 1 3 106 of
cells in PBS-3% BSA. Cells were incubated for 1 hr on ice and then washed
twice. The secondary DyLight 649 donkey anti-rabbit (Biolegend, USA) was
added and incubated for 30 min on ice. After the final wash, samples
were acquired on a FACSCalibur or LSR-II (BD). All the directly conjugated
antibodies used together with Pros1 staining were tested for acetone
fixation.
RT- qPCR
At the indicated time points, cells were harvested and washed, and RNA
was isolated with RNeasy mini kit (QIAGEN, USA) following the
manufacturer’s instructions. Reverse transcription was performed with
RT Superscript III (Invitrogen) or iScript cDNA Synthesis kit (BIO-RAD).
qPCR reactions were performed on Stratagene Mx3000 System with
KAPA SYBR Fast qPCR kit (KAPABIOSYSTEM). The reactions were normal-
ized to housekeeping gene and the specificity of the amplified products
was checked by dissociation curves. Primers used in this paper are listed in
Table S1.
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TNF-a, IL-6, and IL-2 were measured by ELISA Ready-Set-Go (eBioscience,
USA), and IFN-b was tested with Verikine mouse IFN-b ELISA kit (PBL Inter-
feron Source). Culture supernatants were tested at different dilutions following
the manufacturer’s protocol.
T Cell Isolation
Mouse CD4+ T cells were isolated from the spleen by negative selection with
EasySep Mouse CD4+ T cell enrichment kit and following the manufacturer’s
recommendation (STEMCELL Technologies, USA). CD4+CD25 T cells were
then obtained upon depletion of CD25+ cells with EasySepmouseCD25 selec-
tion kit (STEMCELL Technologies). Human naive or total CD4+ T cells were
isolated from PBMCs with the EasySep human naive, CD4 T cell enrichment
kit, according to manufacturer’s protocol (STEMCELL Technologies).
BMDC Differentiation
Bone marrow dendritic cells (BMDC) were obtained from WT or
Axl/Mertk/ (AM/) mice following a standard protocol for differentiation.
Briefly for BMDC, bone marrow progenitors were collected from the femurs of
the indicated mice and 7–10 3 106 cells were cultured in 100 3 20 mm non-
treated cell culture plates in 10 ml of enriched medium, RPMI 1640 plus
10% fetal bovine serum (FBS), 1% penicillin and streptomycin and supple-
mented with 20 ng/mL of recombinant GM-CSF (Peprotech, USA). At days 3
and 5 of cell culture, 10 and 5 ml of enriched media were added, respectively.
On day 6, BMDCs were harvested and 90%, on average, of harvested cells
were positive for CD11c.
Antigen Presentation Assays
For testing Pros1 expression upon antigen presentation, splenic CD4+ T cells
were purified from OT-II mice and cocultured with BMDC in presence of
200 mg/mL of OVA (A5503, SIGMA). After 24 hr, cells were collected and fixed
with cold acetone (20C). Pros1 expression was analyzed on CD4+CD69+ or
CD4+CD69 cells. Pros1 staining was performed according to the protocol
described above.
Splenic CD4+CD25- T cells were purified from C57BL/6 (WT), Pros1flox/flox
Cd4-Cre OT-II (Ctrl OT-II) and Pros1flox/flox Cd4-Cre+ OT-II (Pros1-deficient
OT-II) mice and cocultured with WT or AM/ BMDC at 1:1 ratio in presence
of 50 to 200 mg/mL of OVA (SIGMA). After 24, 48, and 72 hr, cells were
collected. CD86 and CD40 were measured on CD11c+ cells by FACS.
TNF-a, IL-6, and IL-12 were tested by intracellular staining and in the coculture
supernatant by ELISA.
For T cell proliferation assays, CD4+ T cell were isolated from inguinal and
popliteal lymph nodes of immunized mice. 1 3 105 CD4+ T cells stained with
5 mM CFSE were cultured with 3 3 105 irradiated splenocytes in presence of
serial dilutions of OVA, starting at 900 mg/mL. Proliferating T cells were
analyzed by FACS at day 4 by dilution of CFSE. Additionally, IL-2 production
was measured in the coculture supernatant by ELISA.
T Cell—BMDC Coculture
CD4+CD25 cells were isolated by negative selection of CD4+ cells followedby
depletion of CD25+ cells following manufacturer’s instructions (STEMCELL
Technologies). CD4+CD25 T cells were preactivated in serum-free medium
(STEMCELL Technologies) with 10 mg/mL plate bound anti-CD3 and 2 mg/mL
soluble anti-CD28 for 4 hr. BMDCs were then added onto preactivated
T cells at a 1:1 ratio and stimulated with 30 mg/mL of poly I:C or 0.5 mM
CpG-A (Invivogen, USA) for 12–15 hr. CD86 or CD40 were analyzed on
CD11c+. For experiments using recombinant Pros1, preactivated CD4+CD25
T cells from Pros1flox/flox Cd4-Cre+were cocultured with BMDC at 1:1 ratio and
stimulated with 30 mg/mL of Poly I:C or 0.5 mM CpG-A (Invivogen, USA) in
serum-free medium supplemented with 1/10 of conditioned media from
HEK293 expressing recombinant murine Protein S (Prasad et al., 2006).
Competitive Annexin V and Transwell Assay
T cell/BMDC coculture was performed as described above. For competitive
Annexin V assay, 10 mg/mL of recombinant Annexin V (BD-Bioscience, USA)
was added to the T cell culture 1 hr prior to the addition of BMDCs. BMDCs
were added onto preactivated T cells that have been incubated with Annexin
V and the protocol was continued as was previously described. For the trans-well assay, T cells were preactivated on the bottom portion of the transwell for
4 hr and then DCs were added on top of transwell membrane (0.4 mm, Corning,
USA). As a control, DCs were also added at the bottom, directly onto preacti-
vated T cells. The activation of DCs was performed as described above.
Immunization Protocols
CD4+ cells were isolated by negative selection as per manufacturer’s instruc-
tions (STEMCELL Technologies) from the spleen and LN of CD45.2 OT-II
Pros1flox/floxCd4-Cre (Ctrl OT-II) or Cre+ (Pros1/ OT-II). 5 3 106 CD4+
CD45.2 Ctrl OT-II or Pros1/ OT-II were transferred into C57BL/6 CD45.1
recipient mice by retro-orbital injection. After 1 day, mice were challenged
by injection of 50 mg of OVA/5 ng LPS/emulsified in incomplete Freund’s adju-
vant (OVA/LPS/IFA) in one of the rear footpads. Inguinal and popliteal LNswere
removed, total number cells were counted, and Pros1 expression in CD45.2
and DC compartment in CD45.1 were analyzed by FACS 48 and 72 hr after
immunization. Pros1flox/flox Cd4-Cre (Ctrl) or Cre+ (Pros1/) mice, 8 to
10 weeks old, were immunized with 300 mg TNP-KLH (13:1) or 100 mg TNP-
Ficoll (90:1) (both from Biosearch Technologies) in PBS on day 0 and 14.
anti-TNP antibodies were analyzed by ELISA from serum at day 30 after
immunization.
T Cell-Induced Colitis
CD4+CD45RBhiCD25- T cells were isolated from the spleen and lymph nodes
of Pros1flox/flox Cd4-Cre (Ctrl) or Cre+ (Pros1/) mice and transferred intra-
peritoneally (i.p.) into Rag1/ mice (4 3 105 cells/mouse). Colonoscopy was
performed in a blinded fashion for colitis scoring via the Coloview system
(Karl Storz, Germany). In brief, colitis scoring was based on granularity of
mucosal surface, stool consistence, vascular pattern, translucency of the
colon, and fibrin visible (0–3 points for each). Mice were sacrificed about
6–8 weeks after the transfer, and cells isolated from the colon and mesenteric
lymph nodes were analyzed for IFN-g and IL-17A-producing CD4 cells.
Generation of Human Monocyte-Derived DC
We plated 1 3 108 PBMCs in 8 ml of RPMI 1640 plus 2% of human serum in
75 cm2 cell culture flask and incubated at 37C with 5% CO2 for 60 min for
monocyte adherence. After the incubation period, the nonadherent cells
were removed by washing four times with 6–10 ml of PBS. The adherent cells
were cultured in 8 ml RPMI-1640 10% FCS containing 300 U/mL of IL-4 (R&D),
450 U/mL of GM-CSF (R&D) at 37C, and 5%CO2. Cytokine supplementation
was performed again on day 3 by adding 4ml RPMI 1640 10% FCS containing
900 U/mL of IL-4, 1,350 U/mL GM-CSF. Monocyte-derived DCs were har-
vested on day 7.
PROS1 Expression in Human T Cells
Human naive CD4 T cells were obtained from PBMCs with EasySep human
naive CD4+ T cell enrichment kit (STEMCELL Technologies). We cultured 0.5
to 1 3 105 purified naive CD4+ cells in presence (1:1 ratio) or absence of
anti-human CD3/CD28 beads (Life Technologies) plus 3 ng/mL hIL-2 (Pepro-
tech) in serum free medium (STEMCELL, USA) for 1 to 6 days. Cells were har-
vested daily and PROS1 expression was evaluated by qPCR with specific
primers (Table S1) and anti-PROS1-FITC for surface staining by FACS.
Mixed Lymphocyte Reaction (MLR)
Human naive CD4 T cells were obtained by negative selection (STEMCELL
Technologies) and cocultured with monocyte-derived DC, from a different
donor, at 2:1 ratio for 5 days.
For PROS1 blocking experiment, anti-PROS1 (PS7) antibody was added at
day 4, and cells were harvested at day 5. CD40 and CD86 activation markers
were measured on CD11c+ cells by FACS.
Protein S Total Antigen in IBD Patients
This study was approved by the Mayo Clinic Institutional Review Board.
Patients at Mayo Clinic in Arizona with a confirmed diagnosis of active inflam-
matory bowel disease (Crohn’s Disease or Ulcerative Colitis) not on steroids
were enrolled. Exclusion criteria included patients with possible infectious
gastroenteritis, ischemia, or drug-induced disease, as well as those treated
with steroids. Prior to enrollment, all patients were provided informed consent.
Blood was then collected from all patients as well as age-matched adultImmunity 39, 160–170, July 25, 2013 ª2013 Elsevier Inc. 169
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Clinic with the Diagnostica Stago LIATEST Protein S Kit on the Beckman
Coulter ACL TOP (http://www.mayomedicallaboratories.com/test-catalog/
Performance/83049).
Immunohistochemistry
Immunohistochemistry was performed with an automated Benchmark XT IHC
system with ultraview universal DAB Detection Kit (Ventana, Tucson, AZ) and
primary antibodies to PROS1 (Sigma; 1:50) and CD3 (Ventana, 0.45 mg/mL). In
brief, paraffin-embedded formalin fixed tissue sections were processed
according to mild CC1 (PROS1) and standard CC1 (CD3) programs including
incubation with the primary antibodies for 30 min (CD3) or 1 hr (PROS1) at
37C. Appropriate positive (liver) and negative (secondary antibody only)
controls were stained in parallel for each round of immunohistochemistry.
Statistical Analysis
Differences between the means of experimental groups were analyzed with a
two-tailed Student’s t test or ANOVA (Prism GraphPad software). Bonferroni
multiple comparison test was used following two-way ANOVA. p values %
0.05 were considered significant.
SUPPLEMENTAL INFORMATION
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